Skip to main content

Table 1 Inclusion and exclusion criteria

From: Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)

Inclusion criteria

Exclusion criteria

Optimal heart failure therapy in accordance with European and national guidelines

CRT-D/−P implanted < 90 days

LVEF ≤ 0.40

Uncorrected severe valvular disease

eGFR > 30 mL/min/1.73 m2

Non-compliance

BMI < 45 kg/m2

Use of metalozone

NYHA class I–III

NYHA class IV

Age > 18 years

Age > 85 years

 

Dementia

 

Admission for HF < 30 days

If T2D – optimal treatment in accordance with European and national guidelines

Admission for hypoglycemia < 12 months

If T2D – stable doses of anti-glycemic treatment for 30 days

Known sustained VT

If T2D – HbA1c 6.5–10.0%

Symptomatic hypotension and systolic BP < 95 mmHg

 

Unable to perform an exercise test

 

Immobilization

 

Pregnancy

 

Participation in other medical trials

 

Previous intolerance of Empagliflozin or excipients

  1. LVEF left ventricular ejection fraction, eGFR estimated glomerular filtration rate, BMI body mass index, NYHA New York Heart Association, T2D type 2 diabetes, HbA1c hemoglobin A1c, CRT-D/−P cardiac resynchronization therapy with defibrillator (−D) or without defibrillator (−P), HF heart failure, VT ventricular tachycardia, BP blood pressure